The Lancet series led by Jennifer Lees exposes how women with chronic kidney disease face layered disadvantages rooted in male-centric trial design, yet the coverage underplays the systemic pattern across medicine. Observational data from the 2025 Australian GP records study (Lancet Regional Health—Western Pacific; n>1 million records, retrospective cohort design, no reported industry conflicts) showed women 15-20% less likely to receive eGFR testing or specialist referral even at equivalent albuminuria levels. This mirrors broader sex-based inequity documented in cardiovascular trials, where pre-1993 FDA guidelines effectively excluded women of childbearing potential, producing dosing errors that persist today. Fewer than 45% of CKD trial participants are women, dropping to one-third in recent SGLT2 inhibitor and endothelin antagonist studies; crucially, no major RCT has pre-specified sex-stratified safety analyses. One cited example—the atrasentan trial—revealed divergent heart-failure signals only after post-hoc sex breakdown, underscoring how underpowered subgroups (often <30% female) mask harm. Pregnancy compounds the gap: routine antenatal urinalysis misses the 3-6% of reproductive-age women with pre-existing CKD because proteinuria is misattributed to preeclampsia. These findings connect directly to the 2001 IOM report “Exploring the Biological Contributions to Human Health: Does Sex Matter?” and subsequent meta-analyses showing persistent under-enrollment. Policy responses must mandate sex-disaggregated reporting in all phase III protocols and adjust eGFR equations for sex-specific muscle mass, rather than treating the current male-derived reference ranges as neutral.